Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 platform study of EDP1815 and EDP2939 using KLH and imiquimod challenge in healthy volunteers
NL-OMON51644Phase 1Active, not recruiting
- Sponsor
- Evelo Biosciences
- Start
- May 2022
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EDP1815 and EDP2939 in autoimmune disease and inflammatory diseases (5 arms), sponsored by Evelo Biosciences. Primary endpoint: KLH-induced immune reaction after intradermal re-challenge measured as basal flow by laser speckle contrast imaging at 24 hours. Started May 2022; status: active, not recruiting.
02
Drugs
EDP1815EDP2939
03
Conditions
autoimmune diseaseinflammatory diseases
Beyond the preview
Go deeper on NL-OMON51644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51644.